Drug Trial Radar · NCT01096186
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Mar 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Impax Laboratories, LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.
Conditions
- Parkinson's Disease
Interventions
IPX066 95 mgDrug
23.75 - 95 mg CD-LD capsules
IPX066 145 mgDrug
36.25 - 145 mg CD-LD capsules
IPX066 195 mgDrug
48.75 - 195 mg CD-LD capsules
IPX066 245 mgDrug
61.25 - 245 mg CD-LD capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Sum of UPDRS Part II + UPDRS Part IIITime frame: 9 months
Locations
81 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mohammed Ali Parkinson's Center
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
Clinical Trials Inc.
Little Rock, Arkansas
Coastal Neurological Medical Group
La Jolla, California
Coordinated Clinical Research
La Jolla, California
The Parkinson's Institute
Sunnyvale, California
Collaborative NeuroScience Network, Inc.
Torrance, California
Bradenton Research Center, Inc.
Bradenton, Florida
Sunrise Clinical Research
Hollywood, Florida
Renstar Medical Research
Ocala, Florida
Charlotte Neurological Services Parkinson's Disease Treatment Center of S.W. Florida
Port Charlotte, Florida
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida
University of South Florida, Parkinson's Disease and Movement Disorders Center
Tampa, Florida
Medical College of Georgia, Movements Disorders Clinic
Augusta, Georgia
Movement Disorder Center at Idaho Elks Rehabilitation Hospital
Boise, Idaho
Northwestern University, Feinberg School of Medicine, Dept. of Neurology
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Iowa Methodist Medical Center
Des Moines, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Quest Research Institute
Bingham Farms, Michigan
Struthers Parkinson's Center
Golden Valley, Minnesota
UMDNJ Robert Wood Johnson Medical Center, Department of Neurology
New Brunswick, New Jersey
Albany Medical College, Parkinson's Disease and Movement Disorders Center
Albany, New York
David L. Kreitzman, MD, P.C.
Commack, New York
Columbia University Neurological Institute
New York, New York
Institute for Human Performance
Syracuse, New York
Duke University Medical Center Movement Disorders Center
Durham, North Carolina
University Neurology, Inc.
Cincinnati, Ohio
University of Toledo
Toledo, Ohio
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
Medical University of South Carolina
Charleston, South Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
South Puget Sound Neurology
Tacoma, Washington
Wisconsin Institute for Neurologic and Sleep Disorders
Milwaukee, Wisconsin
London Health Sciences Centre, University Hospital
London, Ontario, Canada
Parkinson's & Neurodegenerative Disorder Clinic
Ottawa, Ontario, Canada
Ottawa Hospital Civic Site
Ottawa, Ontario, Canada
Quebec Memory & Motor Skills Disorders Clinic
Québec, Quebec, Canada
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.